Today: 20 May 2026
Browse Category

NYSE:CRK 6 November 2025 - 23 December 2025

Comstock Resources Stock (CRK) Rises on Dec. 23, 2025: Latest News, Analyst Forecasts, and the 2026 Natural Gas Outlook

Comstock Resources Stock (CRK) Rises on Dec. 23, 2025: Latest News, Analyst Forecasts, and the 2026 Natural Gas Outlook

Comstock Resources shares rose about 4% to $22.70 in light pre-Christmas trading on December 23, 2025, with volume around 75,000 shares. The move follows news of a $430 million sale of Shelby Trough assets in East Texas, expected to close by year-end. Comstock projects a pre-tax gain of $290–$310 million from the divestiture. Apex Natural Gas, backed by Citadel, was reported as the buyer, though not confirmed by Comstock.
23 December 2025
···
Comstock Resources (CRK) Stock: December 11, 2025 News, Price Drop, Forecasts and AI-Powered Gas Demand Outlook

Comstock Resources (CRK) Stock: December 11, 2025 News, Price Drop, Forecasts and AI-Powered Gas Demand Outlook

Comstock Resources shares fell to $21.6 on December 11, down 6% for the day and nearly 10% for the week, despite remaining over 40% higher than a year ago. The stock has dropped 21% since December 8, with trading volume below average and short interest near 20%. TradingView and Intellectia show mixed technical signals, while Zacks and NextEra Energy highlight Comstock’s potential as gas prices rebound.
11 December 2025
··
Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources shares rose 5.5% to $21.14 midday after reporting Q3 revenue of $449.9 million and adjusted EPS of $0.09, citing higher gas prices and lower costs. The company advanced a $430 million Shelby Trough asset sale, expected to close in December 2025. Three new Western Haynesville wells averaged initial production of 32 MMcf/d. Liquidity stood at $939.2 million as of September 30.
6 November 2025
···

Stock Market Today

  • SpaceX IPO Filing Could Propel Elon Musk to Trillionaire Status
    May 20, 2026, 5:46 PM EDT. SpaceX's recent S-1 filing signals a potential initial public offering (IPO) that could surpass the 2020 record set by Saudi Aramco as the largest IPO in history. The deal is expected to significantly increase the valuation of SpaceX, potentially making CEO Elon Musk a trillionaire. This move highlights the growing investor interest in private spaceflight companies and the expanding market for space exploration-related ventures.

Latest articles

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

20 May 2026
Xanadu Quantum Technologies’ shares surged 20.4% to $14.13 Wednesday, rebounding after a sharp May decline. The company reported Q1 revenue of $2.83 million and a net loss of $20.6 million, with 43.3 million Class B shares outstanding and a prospectus covering up to 293.7 million more. Other quantum stocks also rose. Xanadu is in talks for up to $285 million in Canadian government support.
MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
Go toTop